Search

everythinglearnresearchcommunity

for

Search:↓

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Sonidegib is effective and safe for treating advanced basal cell carcinoma, but biopsies are needed to confirm tumor clearance.

Deucravacitinib helped a man regrow hair significantly.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Oleoylethanolamide (OEA) safely boosts fat production in skin cells and may help treat dry skin and reduce inflammation.

Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.

Immune cell-targeting biologics show potential for treating alopecia areata but need better-targeted therapies.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

A woman with severe hair loss was successfully treated with the drug adalimumab.

Baricitinib is effective and safe for treating severe alopecia areata.

Upadacitinib effectively treats pyoderma gangrenosum.

TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.

Papulopustular rosacea is an inflammatory skin condition treatable with lifestyle changes and medications.

Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.

Surgical treatments and topical tofacitinib may help with vitiligo-related eyebrow and eyelash whitening, but more research is needed.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

A new skin disease in four Labrador retrievers responded well to immunosuppressive treatment.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

JAK1 inhibitors can help reduce itchiness in atopic dermatitis.

New treatments for ichthyosis, like protein replacement and gene therapy, show promise and may become standard care.

Ustekinumab treatment didn't prevent frontal fibrosing alopecia.

Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.

Accurate diagnosis of RDEB-mitis in older adults is crucial for proper management without immunosuppressants.